|
For
immediate release
|
3 July 2024
|
ALLIANCE PHARMA
PLC
("Alliance" or the "Group")
Annual Report and Accounts
and Notice of AGM
Alliance Pharma plc (AIM: APH), the
international healthcare group, announces that the Annual Report & Accounts for
the year ended 31 December 2023 (the "2023 Annual Report") was
published and made available on 19 June
2024 on the Group's website, www.alliancepharmaceuticals.com.
Printed copies of the 2023 Annual Report were mailed
to those shareholders who have opted out of receiving electronic
communications from the Group.
Alliance also announces that the
Notice of the 2024 Annual General Meeting, which will be held at
10.00 am on 29 July 2024, has been made available on the
Group's website, www.alliancepharmaceuticals.com;
and printed copies were mailed to those
shareholders who have opted out of receiving electronic
communications from the Group.
Printed copies of both documents are
also available by contacting Burson Buchanan by email at
alliancepharma@buchanan.uk.com or by telephoning 020 7466
5000.
For
further information:
|
Alliance Pharma plc
|
+ 44 (0)1249
466966
|
|
Head of Investor Relations &
Corporate Communications:
Cora McCallum
|
+ 44
(0)1249 705168
|
|
ir@allianceph.com
|
|
|
|
|
|
Burson Buchanan
|
+ 44 (0)20 7466
5000
|
|
Mark Court / Sophie Wills
|
|
|
alliancepharma@buchanan.uk.com
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint
Broker)
|
+ 44 (0)20 7260
1000
|
|
Freddie Barnfield / Duncan Monteith
/ Sher Shah
|
|
|
Investec Bank plc (Joint Broker)
|
+ 44 (0) 20 7597
5970
|
|
Patrick Robb / Maria Gomez de
Olea
|
|
About Alliance
Alliance Pharma plc (AIM: APH) is a
growing consumer healthcare company. Our purpose is to empower
people to make a positive difference to their health and wellbeing
by making our trusted and proven brands available around the
world.
We deliver organic growth through
investing in our priority brands and channels, in related
innovation, and through selective geographic expansion to increase
the reach of our brands. Periodically, we may look to enhance our
organic growth through selective, complementary
acquisitions.
Headquartered in the UK, the Group
employs around 285 people based in locations across Europe, North
America, and the Asia Pacific region. By outsourcing our
manufacturing and logistics we remain asset-light and focused on
maximising the value we can bring, both to our stakeholders and to
our brands.
For more information on Alliance,
please visit our website: www.alliancepharmaceuticals.com